You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors
SBC: BIOPTICS TECHNOLOGY LLC Topic: 102ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Time-resolved laser speckle contrast imaging of resting-state functional connectivity in neonatal brain
SBC: BIOPTICS TECHNOLOGY LLC Topic: 103ABSTRACT Continuous monitoring of neonatal brain development is crucial for effective management of brain injury and associated complications, thus reducing healthcare burden and costs. One rapidly developing method for early characterization of abnormal brain development is to map resting-state functional connectivity (rs-FC) across distinct regions of the brain. However, currently available neur ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
I-RED Southeast XLerator Network
SBC: XLERATEHEALTH, LLC Topic: 500Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Wicked Smart Pad: Washable Sensorized Bedding for the Prevention and Detection of Moisture Events
SBC: Wicked Sheets, LLC Topic: NIAProject Summary/Abstract: Due to decreased mobility, deterioration in activities of daily living, and neurological decline that contributes to loss of bladder control, incontinence is a leading comorbidity for those individuals suffering from Alzheimer’s disease and related dementias (ADRD). Further, individuals with incontinence are susceptible to the development of pressure ulcers (PUs), with ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
SBC: Antiger Therapeutics Inc. Topic: NIAIDPROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health